Clinical progression: need for NIV, IMV, ECMO, or renal replacement therapy at day 5 (group 5, 6 or 7) · hospitalised individuals with COVID‐19 (moderate to severe disease)
It is very uncertain whether bamlanivimab changes clinical progression: need for NIV, IMV, ECMO, or renal replacement… compared with placebo (very low certainty).
1 finding from 1 review
Quality of life · hospitalised individuals with COVID‐19 (moderate to severe disease)
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Time to hospital discharge · hospitalised individuals with COVID‐19 (moderate to severe disease)
Bamlanivimab showed no clear difference in time to hospital discharge up to 26.10.2020, absolute effects for… compared with placebo (low certainty).
1 finding from 1 review
Grades 3 and 4 adverse events · hospitalised individuals with COVID‐19 (moderate to severe disease)
Bamlanivimab showed no clear difference in adverse events: grades 3 and 4 by day 30 compared with placebo (low certainty).
1 finding from 1 review
Serious adverse events by day 30 · hospitalised individuals with COVID‐19 (moderate to severe disease)
Bamlanivimab showed no clear difference in serious adverse events by day 30 compared with placebo (low certainty).
1 finding from 1 review
Mortality by day 30 · hospitalised individuals with COVID‐19 (moderate to severe disease)
Casirivimab/imdevimab showed no clear difference in mortality by day 30 compared with usual care alone (moderate certainty).
1 finding from 1 review
Mortality by day 60 · hospitalised individuals with COVID‐19 (moderate to severe disease)
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Clinical progression: IMV or death (≥ 7 WHO scale) · hospitalised individuals with COVID‐19 (moderate to severe disease)
Casirivimab/imdevimab showed no clear difference in clinical progression: need for IMV or death (WHO ≥ 7) compared with usual care alone (moderate certainty).
1 finding from 1 review
Quality of life · hospitalised individuals with COVID‐19 (moderate to severe disease)
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Hospital discharge alive by day 30 · hospitalised individuals with COVID‐19 (moderate to severe disease)
Casirivimab/imdevimab showed no clear difference in hospital discharge alive by day 30 compared with usual care alone (moderate certainty).
1 finding from 1 review
Grades 3 and 4 adverse events · hospitalised individuals with COVID‐19 (moderate to severe disease)
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Serious adverse events by day 30 · hospitalised individuals with COVID‐19 (moderate to severe disease)
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
All‐cause mortality at day 28 · people with moderate to severe disease (WHO scale 4–9); all studies contributing results to the summary of findings table included people…
Azithromycin showed no clear difference in all‐cause mortality at day 28 compared with placebo or standard of care alone (high certainty).
1 finding from 1 review
Clinical worsening: need for invasive mechanical ventilation, or death at up to day 28 · people with moderate to severe disease (WHO scale 4–9); all studies contributing results to the summary of findings table included people…
Azithromycin showed no clear difference in worsening of clinical status: participants with clinical… compared with placebo or standard of care alone (moderate certainty).
1 finding from 1 review
Clinical improvement: discharged alive ( · people with moderate to severe disease (WHO scale 4–9); all studies contributing results to the summary of findings table included people…
Azithromycin showed no clear difference in improvement of clinical status: participants discharged alive at day… compared with placebo or standard of care alone (moderate certainty).
1 finding from 1 review
Quality of life at longest · people with moderate to severe disease (WHO scale 4–9); all studies contributing results to the summary of findings table included people…
1 finding from 1 review
Serious adverse events during the study period · people with moderate to severe disease (WHO scale 4–9); all studies contributing results to the summary of findings table included people…
Azithromycin showed no clear difference in serious adverse events during the study period compared with placebo or standard of care alone (moderate certainty).
1 finding from 1 review
Adverse events during treatment period · people with moderate to severe disease (WHO scale 4–9); all studies contributing results to the summary of findings table included people…
Azithromycin showed no clear difference in any adverse events during the study period compared with placebo or standard of care alone (low certainty).
1 finding from 1 review
Arrhythmias · people with moderate to severe disease (WHO scale 4–9); all studies contributing results to the summary of findings table included people…
Azithromycin showed no clear difference in cardiac arrhythmias during the study period compared with placebo or standard of care alone (moderate certainty).
1 finding from 1 review
Death at hospital discharge · individuals with moderate to severe disease
1 finding from 1 review